Terry A Jacobson
Overview
Explore the profile of Terry A Jacobson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
174
Citations
8111
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maki K, Kirkpatrick C, Cheeley M, Jacobson T
Curr Atheroscler Rep
. 2024 Nov;
27(1):5.
PMID: 39556289
Purpose Of Review: Statins are first-line pharmacotherapy for the treatment of elevated low-density lipoprotein cholesterol and are generally well-tolerated. However, some patients may experience statin-associated muscle symptoms (SAMS). This paper...
2.
Soffer D, Marston N, Maki K, Jacobson T, Bittner V, Pena J, et al.
J Clin Lipidol
. 2024 Sep;
18(5):e647-e663.
PMID: 39256087
This National Lipid Association (NLA) Expert Clinical Consensus provides an overview of the physiologic and clinical considerations regarding the role of apolipoprotein B (apoB) measurement to guide clinical care based...
3.
Bays H, Kirkpatrick C, Maki K, Toth P, Morgan R, Tondt J, et al.
Obes Pillars
. 2024 May;
10:100108.
PMID: 38706496
Background: This joint expert review by the Obesity Medicine Association (OMA) and National Lipid Association (NLA) provides clinicians an overview of the pathophysiologic and clinical considerations regarding obesity, dyslipidemia, and...
4.
Bays H, Kirkpatrick C, Maki K, Toth P, Morgan R, Tondt J, et al.
J Clin Lipidol
. 2024 Apr;
18(3):e320-e350.
PMID: 38664184
Background: This joint expert review by the Obesity Medicine Association (OMA) and National Lipid Association (NLA) provides clinicians an overview of the pathophysiologic and clinical considerations regarding obesity, dyslipidemia, and...
5.
Koschinsky M, Bajaj A, Boffa M, Dixon D, Ferdinand K, Gidding S, et al.
J Clin Lipidol
. 2024 Apr;
18(3):e308-e319.
PMID: 38565461
Since the 2019 National Lipid Association (NLA) Scientific Statement on Use of Lipoprotein(a) in Clinical Practice was issued, accumulating epidemiological data have clarified the relationship between lipoprotein(a) [Lp(a)] level and...
6.
Szarek M, Bhatt D, Miller M, Brinton E, Jacobson T, Tardif J, et al.
J Am Coll Cardiol
. 2024 Mar;
83(16):1529-1539.
PMID: 38530686
Background: Elevated lipoprotein(a) (Lp[a]) concentrations are associated with increased cardiovascular event risk even in the presence of well-controlled low-density lipoprotein cholesterol levels, but few treatments are documented to reduce this...
7.
Sayah N, Bhatt D, Miller M, Brinton E, Jacobson T, Ketchum S, et al.
Eur Heart J
. 2024 Jan;
45(13):1173-1176.
PMID: 38252107
No abstract available.
8.
Weintraub W, Bhatt D, Zhang Z, Dolman S, Boden W, Bress A, et al.
J Am Heart Assoc
. 2023 Dec;
13(1):e032413.
PMID: 38156550
Background: In 3146 REDUCE-IT USA (Reduction of Cardiovascular Events With Icosapent Ethyl Intervention Trial USA) participants, icosapent ethyl (IPE) reduced first and total cardiovascular events by 31% and 36%, respectively,...
9.
Miller M, Bhatt D, Brinton E, Jacobson T, Steg P, Lira Pineda A, et al.
Eur Heart J Open
. 2023 Nov;
3(6):oead114.
PMID: 38035037
Aims: Metabolic syndrome (MetSyn) is associated with high risk of cardiovascular (CV) events, irrespective of statin therapy. In the overall REDUCE-IT study of statin-treated patients, icosapent ethyl (IPE) reduced the...
10.
Virani S, Aspry K, Dixon D, Ferdinand K, Heidenreich P, Jackson E, et al.
Am J Prev Cardiol
. 2023 Mar;
13:100472.
PMID: 36970638
Despite the established role of low-density lipoprotein cholesterol (LDL-C) as a major risk factor for cardiovascular disease (CVD), and the persistence of CVD as the leading cause of morbidity and...